By elevating patient perspectives from an afterthought to a core part of the process, payers can create a system that aligns ...

Although inflation appears to be cooling — for now — experts warn that the 2026 COLA may not be enough to keep up with ...

The Most Favored Nation order is unlikely to deliver broad, sustained savings without triggering legal challenges, ...

"I'm not going to second-guess myself."Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like ...

Following President Trump's Most Favored Nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.

UnitedHealth Group faces real PBM reform risks, but legal paths, financials, and market pricing suggest opportunity in ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, ...

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big ...

A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often ...

The executive order would require other countries to pay more for medications so that Americans could pay less. But experts ...

FRIDAY, May 16, 2025 (HealthDay News) — Low-income Medicare beneficiaries are more likely to die if they lose access to ...